跳到主要內容區塊
羅承翔 放射物理科主任

羅承翔 放射物理科主任

Cheng-Hsiang Lo

現職

三軍總醫院放射腫瘤部主治醫師 2016年1月~迄今
三軍總醫院放射腫瘤部放射物理科主任 2020年9月~迄今

學位

國防醫學院醫學系 101 期,民國 97 年 (2008) 畢業

進修

日本International Training course on Carbon-ion Radiotherapy (ITCCIR)訓練

教職

國防醫學院醫學系放射腫瘤學科臨床助理教師 2012年8月~2014年7月
國防醫學院醫學系放射腫瘤學科臨床講師 2014年8月~迄今
教育部 部定講師 2016年2月~ 2019年7月
教育部 部定助理教授 2019年8月~迄今

經歷

三軍總醫院放射腫瘤部住院醫師 2011年7月~2014年7月
三軍總醫院放射腫瘤部總住院醫師 2014年8月~ 2015年7月
三軍總醫院放射腫瘤部資深住院醫師 2015年8月~ 2015年12月
三軍總醫院放射腫瘤部主治醫師 2015年12月~ ~迄今
三軍總醫院澎湖分院安寧病房主任 2017年7月~ 2018年6月
影像導引斷層式放射治療中心主任 2020年5月~2021年1月

專長學科

放射腫瘤學
頭頸部腫瘤、肺癌、乳癌、肝癌、直腸癌、攝護腺癌等腫瘤放射治療
影像導引放射治療
立體定位放射治療
手術中放射治療

專業證照

放射腫瘤科專科醫師
台灣癌症安寧緩和專科醫師
頭頸癌專科醫師

論文發表

1. Chen PK, Chiu SH, Tsai MT, Chang KH, Chang WC, Lin HH, Lo CH, Huang GS, Chang PY. Combination therapy of sorafenib and drug-eluting bead transarterial chemoembolization for advanced hepatocellular carcinoma with and without hepatic arteriovenous shunt. J Chin Med Assoc . 2022 Feb 3. Online ahead of print [SCI]

2. Hsiang CW, Huang WY, Yang JF, Shen PC, Dai YH, Wang YF, Lin CS, Chang WC, Lo CH*. Dynamic Changes in Neutrophil-to-Lymphocyte Ratio are Associated with Survival and Liver Toxicity Following Stereotactic Body Radiotherapy for Hepatocellular Carcinoma. J Hepatocell Carcinoma . 2021 Oct 29;8:1299-1309. [SCI]

3. Chang WC, Hsu HH, Chiu SH, Huang WY, Lo CH, Lin HH, Huang PC, Shih YL, Wan YL. Transcatheter Arterial Chemoembolization with Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma: Recommended Selection for Small-Caliber ( <100 μm) Beads. J Hepatocell Carcinoma . 2021 Aug 14;8:937-949. [SCI]

4. Lo CH, Lee HL, Hsiang CW, et. al. Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival and Liver Toxicity om Patients with Hepatocellular Carcinoma Treated with Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 Sep 6:S0360-3016(20)34224-3. Online ahead of print. Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):474-484.[SCI]

5. Wang YF, Dai YH, Lin CS, Chang HC, Shen PC, Yang JF, Hsiang CW, Lo CH*, Huang WY*. Clinical outcome and pathologic correlation of stereotactic body radiation therapy as a bridge to transplantation for advanced hepatocellular carcinoma: a case series. Radiat Oncol. 2021 Jan 14;16(1):15 [SCI]

6. Lo CH, Huang WY, Hsiang CW, et al. Prognostic Significance of Apparent Diffusion Coefficient in Hepatocellular Carcinoma Patients treated with Stereotactic Ablative Radiotherapy. Sci Rep. 2019 Oct 2:9(1): 14157. [SCI]

7. Yang JF, Lo CH, Lee MS, et. al. Stereotactic Ablative Radiotherapy versus Conventionally Fractionated Radiotherapy in the treatment of Hepatocellular Carcinoma with Portal Vein Invasion: a Restrospective Analysis. Radiat Oncol. 2019 Oct 22;14(1):180. [SCI]

8. Shen PC, Chang WC, LO CH, et. al. Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys.2019 Oct 1:105(2):307-318. [SCI]

9. Lo CH, Huang WY, Chang WC, Chao HL, Lin KT, Yang JF, Cheng YC, Lin CS. Application of Stereotactic Ablative Radiotherapy in Hepatocellular Carcinoma Patients with Child–Turcotte–Pugh Class B Liver Function. J Med Sci. 38(5), 204, 2018

10. Chao HL, Liu SC, Tsao CC, Lin KT, Lee SP, Lo CH, Huang WY, Liu MY, Jen YM, Lin CS.Dose escalation via brachytherapy boost for nasopharyngeal carcinoma in the era of intensity-modulated radiation therapy and combined chemotherapy. J Radiat Res. 2017 Sep 1;58(5):654-660. [SCI]

11. Lo CH, Liu MY, Lee MS,Yang JF, Jen YM, Lin CS, Chao HL, Shen PC, Huang WY. Comparison between Child-Turcotte-Pugh and albumin-bilirubin scores in assessing the prognosis of hepatocellular carcinoma after stereotactic ablative radiotherapy. Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):145-152. [SCI]

12. Lo CH, Yang JF, Liu MY, Jen YM, Lin CS, Chao HL, Huang WY. Survival and prognostic factors for patients with advanced hepatocellular carcinoma after stereotactic ablative radiotherapy. PLoS One. 2017 May 17;12(5): e0177793. [SCI]

13. Fan CY, Huang WY, Lin CS, Su YF, Lo CH, Tsao CC, Liu MY, Lin CL, Kao CH. Risk of second primary malignancies among patients with prostate cancer: A population-based cohort study. PLoS One. 2017 Apr 6;12(4): e0175217. [SCI]

14. Huang WY, Ho CL, Lee CC, Hsiao CW, Wu CC, Jao SW, Yang JF, Lo CH, Chen JH. Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer. PLoS One. 2017 Mar 22;12(3): e0174280. [SCI]

15. Liu MY, Lo CH, Lin CS, Chao HL, Yang JF, Lin KT, Fan CY, Su YF, Huang WY. Stereotactic ablative radiotherapy for patients with unresectable or medically inoperable cholangiocarcinoma. Tumori. 2017 May 12;103(3):236-241. [SCI]

16. Yang JF, Lo CH, Huang WY. Is Stereotactic Body Radiotherapy Better Than Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma? J Clin Oncol. 2016 Aug 10;34(23):2797. [SCI]

17. Yang JF, Lee MS, Lin CS, Chao HL, Chen CM, Lo CH, Fan CY, Tsao CC, Huang WY. Long-term breast cancer patient outcome after adjuvant radiotherapy using intensity-modulated radiotherapy or conventional tangential radiotherapy. Medicine(Baltimore). 2016 Mar;95(11): e3113. [SCI]

18. Fan CY, Chao CL, Huang WY, Lin CS, Chen CM, Lo CH. Stereotactic ablative radiotherapy with CyberKnife in the treatment of locally advanced prostate cancer: preliminary results. Tumori. 2015 Nov-Dec;101(6):684-91. [SCI]

19. Lo CH, Huang WY, Lin KT, Lin MJ, Lin TP, Jen YM. Repeated stereotactic ablative radiotherapy using Cyberknife for patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2014 Nov;29(11):1919-25 [SCI]

20. Lo CH, Huang WY, Lee MS, Lin KT, Lin TP, Chang PY, Fan CY, Jen YM Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma patients who failed or were unsuitable for transarterial chemoembolization. Eur J Gastroenterol Hepatol. 2014 Mar;26(3):342-52 [SCI]

21. Lo CH, Huang WY, Chao HL, Lin KT, Jen YM. Novel application of stereotactic ablative radiotherapy using CyberKnifeR for early-stage renal cell carcinoma in patients with pre-existing chronic kidney disease: initial clinical experiences Oncol Lett. 2014 Jul;8(1): 355-360 [SCI]

22. Li PF, Lo CH, Yang SH, Chung PY, Ho CL. Pulmonary pleomorphic carcinoma with multiple metastases to the right posterior knee complicated by paraneoplastic hypercalcemia. Oncol Lett. 2014 Feb;7(2): 452-454 [SCI]

23. Lin KT, Huang WY, Lin CC, Jen YM, Lin CS, Lo CH, Kao CH. Subsequent risk of nasopharyngeal carcinoma among patients with allergic rhinitis: A nationwide population-based study. Head Neck 2015 Mar:37(3): 413-7 [SCI]

24. Huang WY, Kao CH, Huang WS, Chen CM, Chang LP, Lee MS, Chao HL, Chiu CH, Lo CH, Jen YM. 18F-FDG PET and Combined 18F-FDG-Contrast CT Parameters as Predictors of Tumor Control for Hepatocellular Carcinoma After Stereotactic Ablative Radiotherapy. J Nucl Med 2013; 54:1710-1716 [SCI]

25. Lo CH, Cheng SN, Lin KT, Jen YM. Successful treatment of infantile fibrosarcoma spinal metastasis by chemotherapy and stereotactic hypofractionated radiotherapy. J Korean Neurosurg Soc. 2013 Dec;54(6):528-31 [SCI]

26. Lo CH, Jen YM, Tsai WC, Chung PY, Kao WY. Rapidly evolving asymptomatic eosinophilia in a patient with lung adenocarcinoma causes cognitive disturbance and respiratory insufficiency: Case report. Oncol Lett. 2013 Feb;5(2): 495-498 [SCI]

語音服務
瀏覽人次:6080
更新時間:2022/12/4 下午 03:00:23

收起